Bristol Myers Squibb’s GPRC5D-directed CAR-T, Imdelltra (tarlatamab), paired with AstraZeneca’s Imfinzi (durvalumab), met its primary overall survival endpoint in a phase III trial for first-line maintenance treatment in extensive-stage small-cell lung cancer. The win positions the program for potential expansion in earlier settings if confirmatory results hold. Separately, BMS reported Phase 2 progress for its GPRC5D CAR-T in relapsed and refractory multiple myeloma, claiming improvements in overall and complete response rates in a heavily pretreated population. Analysts framed the data as a “derisking” step that differentiates the patient segment BMS is targeting. Together, the updates underscore how cell-therapy developers are sharpening population-selection strategies—pushing into more specific lines of therapy and combinations—to manage efficacy risks in difficult-to-treat disease landscapes. For sponsors, these datasets also reinforce the importance of endpoint selection and positioning language in investor interpretation ahead of regulatory milestones.